BGLC
BioNexus Gene Lab Corp Common stock
NASDAQ: BGLC · BASIC MATERIALS · SPECIALTY CHEMICALS
$2.02
-4.14% today
Updated 2026-06-05
Market cap
$5.56M
P/E ratio
—
P/S ratio
1.05x
EPS (TTM)
$-1.49
Dividend yield
—
52W range
$2 – $16
Volume
0.0M
WallStSmart proprietary scores
26
out of 100
Grade: F
Strong Sell
Investment rating
2.0
Growth
F8.5
Quality
A2.0
Profitability
F5.0
Valuation
C+3/9
Piotroski F-Score
Weak
7.5
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
—
—
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Altman Z 7.52 — safe zone
+ Debt/equity 0.03x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at -54.70%
- Negative free cash flow $-148000.00
- Revenue declining -98.90% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $10.93M | $9.77M | $9.51M | $7.42M | $5.31M |
| Net income | $-355966.00 | $-2.63M | $-1.60M | $-2.98M | $-543575.00 |
| EPS | — | — | — | — | $-1.49 |
| Free cash flow | $489857.00 | $-1.91M | $-2.46M | $-1.88M | $-148000.00 |
| Profit margin | -3.26% | -26.91% | -16.81% | -40.20% | -54.70% |
Peer comparison
Smart narrative
BioNexus Gene Lab Corp Common stock trades at $2.02. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 7.52, it sits in the safe zone. TTM revenue stands at $5.31M. with profit margins at -54.70%.
Frequently asked questions
What is BioNexus Gene Lab Corp Common stock's stock price?
BioNexus Gene Lab Corp Common stock (BGLC) trades at $2.02, on a P/S of 1.0x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is BioNexus Gene Lab Corp Common stock overvalued?
BioNexus Gene Lab Corp Common stock carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is BioNexus Gene Lab Corp Common stock's revenue?
BioNexus Gene Lab Corp Common stock's trailing twelve-month revenue is $5.31M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
BioNexus Gene Lab Corp Common stock's Altman Z-Score is 7.52, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorBASIC MATERIALS
IndustrySPECIALTY CHEMICALS
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.05x
ROE-35.89%
Beta2.19
50D MA$2.19
200D MA$3.68
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—